Thermo Fisher Scientific
Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
Premium
As economic and practical challenges of next-gen sequencing have eased in recent years, more groups are bringing comprehensive cancer genomic testing in house.
A Spanish team is hoping it can further validate promising early results using TCR characteristics to predict the success or failure of pre-surgery chemoimmunotherapy.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Japanese Health Ministry Clears Thermo Fisher Scientific Oncomine Assay as CDx for Lung Cancer Drug
The Oncomine Dx Target Test can now be used to identify patients with RET-fusion positive NSCLC who may be treated with Eli Lilly's selpercatinib.
Thermo Fisher Scientific, AstraZeneca Team up to Develop CDx for Targeted Drugs
The next-generation sequencing based companion diagnostics will be paired with targeted therapies that are being developed for several diseases.
Jul 11, 2019